BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/11/2014 8:39:00 PM | Browse: 558 | Download: 524
Publication Name World Journal of Gastroenterology
Manuscript ID 5330
Country/Territory Japan
Received
2013-08-30 09:56
Peer-Review Started
2013-08-30 14:07
To Make the First Decision
2013-10-29 12:29
Return for Revision
2013-09-29 14:28
Revised
2013-10-08 22:45
Second Decision
2013-11-29 11:10
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-11-30 01:23
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
2013-12-04 16:52
Typeset the Manuscript
2013-12-11 20:53
Publish the Manuscript Online
2014-01-20 16:41
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology and Hepatology
Manuscript Type Topic Highlights
Article Title Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List Toru Ishikawa
Funding Agency and Grant Number
Corresponding Author Toru Ishikawa, MD, PhD, Department of Gastroenterology and Hepatology, Saiseikai Niigata Daini Hospital, 280-7 Teraji, Niigata 950-1104, Japan. toruishi@ngt.saiseikai.or.jp
Key Words Hepatocellular carcinoma; Hepatitis B virus; Recurrence; Nucleotide analogues; Interferon
Core Tip Recent advances in treatment modalities have improved the survival rate of patients with hepatocellular carcinoma (HCC). However, hepatitis B virus (HBV)-related HCC has a much higher recurrence rate. In this article, we describe strategies for reducing recurrent HCC using anti-viral therapy for HBV infection.
Publish Date 2014-01-20 16:41
Citation Ishikawa T. Anti-viral therapy to reduce recurrence and improve survival in hepatitis B virus-related hepatocellular carcinoma. World J Gastroenterol 2013; 19(47): 8861-8866
Url http://www.wjgnet.com/1007-9327/full/v19/i47/8861.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i47.8861
Full Article (PDF) WJG-19-8861.pdf
Manuscript File 5330-Review.doc
Answering Reviewers 5330-Answering reviewers.pdf
Copyright License Agreement 5330-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 5330-Language certificate.pdf
Peer-review Report 5330-Peer Review(s).pdf
Scientific Editor Work List 5330-Scientific editor work list.doc